Insider Purchases: Inside the Buy
Tag: insider buying
🚜 Tractor Supply (TSCO): Why CEO Hal Lawton Just Bought $501,000 of Stock After a 46% Selloff
After falling roughly 46% from its all-time high, Tractor Supply has become one of retail's more intriguing turnaround candidates. CEO Hal Lawton recently invested more than $500,000 of his own money while institutions continue to own over 95% of the company. We examine whether today's valuation reset represents genuine opportunity—or simply reflects slowing fundamentals that still need to improve.
💊 Pfizer (PFE): Why a Former Vanguard CEO Just Bought Nearly $1 Million of This 6.4% Dividend Stock
Pfizer has spent years under pressure following the collapse of pandemic-era revenues. Yet beneath the headlines, the company's non-COVID business is strengthening, oncology is expanding through Seagen, and two highly respected directors—including former Vanguard CEO and CIO Tim Buckley—recently invested nearly $2 million of their own money. We examine whether Wall Street is overlooking one of healthcare's most compelling value opportunities.
🌿 SiteOne Landscape Supply (SITE): CEO Buys $816K as This $36B Market Leader Nears 52-Week Lows
SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.
🌾 Bunge (BG): Why This Agribusiness Compounder Looks Attractive Again After a 43% Rally
Bunge isn't merely a grain trader—it's one of the world's most important agricultural infrastructure companies. After a 43% rally from our 2025 recommendation, a healthy pullback, another insider purchase, stronger earnings guidance and accelerating Viterra synergies make the long-term investment story compelling once again.
🧪 Huntsman (HUN): CEO Buys $981K as Wall Street Overlooks a $12 Billion Chemical Merger
Huntsman isn't simply a cyclical chemical company anymore. Between repeated insider buying, a transformational $12.5 billion merger with Olin, trading at just 0.64x book value and more than $400 million in projected synergies, investors may be looking at one of the market's more intriguing industrial turnaround opportunities.
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.
❄️ Hudson Technologies (HDSN): The Entire Board Bought. Should Investors Pay Attention?
Hudson Technologies isn't the hottest stock on Wall Street—but it may be one of the coolest. After synchronized insider buying from management, directors and a major shareholder, we examine whether this overlooked refrigerant specialist deserves a closer look.
🥫 The Great Canned-Good Reset: Inside Conagra's Dividend Cut, Brase's $510K Skin-in-the-Game, and the 10x Forward P/E Floor
Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.
⚛️ Standard Nuclear (NYSE: STDN): Fascinating Technology. Speculative Stock.
Standard Nuclear may help power tomorrow's AI-driven economy, but investing isn't about buying exciting technologies at any price. We examine STDN's IPO, Decisive Point's $19 million purchase, its impressive backlog, and why patience may be the smartest move.